Efficacy and safety of ketogenic diet in glioblastoma: an updated systematic review and meta-analysis
Neurological Sciences · 2026-05 · 47 (5)
DOI: 10.1007/s10072-026-09035-y ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Neurological Sciences, online erschienen am 25.04.2026. Verfasst von Jawaria Firdous und 15 weiteren Autor:innen. Beteiligte Einrichtung: Punjab Medical College, Punjab, Pakistan. Hauptthemen laut MEDLINE: Diet, Ketogenic, Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Glioblastoma (GBM) remains the most common and lethal primary central nervous system tumor, with a median survival of only 14.6 months under standard care. The tumor’s characteristic "Warburg effect"—a dependency on aerobic glycolysis for energy—creates a metabolic vulnerability. This review evaluates the efficacy and safety of the ketogenic diet (KD) as an adjunctive metabolic therapy aimed at exploiting this glucose dependency.
Methods
This PRISMA-compliant systematic review updates clinical evidence by synthesizing data from databases from 2000 to September 2025. We searched PubMed, Embase, Cochrane, and Web of science for human studies assessing the ketogenic diet (KD) in glioblastoma and high-grade gliomas. Primary outcomes included overall survival (OS), progression-free survival (PFS), feasibility, and adverse events. Study quality was assessed using Joanna Briggs Institute tools. Prospero registration: CRD420251232650.
Results
Forty-one studies were included, ranging from randomized trials to case series and abstracts, utilizing interventions such as the classic 4:1 ketogenic diet, Modified Atkins Diet, and calorie restriction. Adherence was high (> 75% maintained nutritional ketosis). Recent data indicate significant survival benefits; adherent cohorts achieved a median OS of 29.4 months vs 14.6 months in historical controls; with 66.7% 3-year survival rate. The diet was well-tolerated, with adverse events limited to mild gastrointestinal symptoms and fatigue. No Grade 3/4 diet-related toxicities reported.
Conclusion
Current evidence supports the KD as a safe, feasible, and biologically rational adjunct to standard glioblastoma treatment. It demonstrates potential to prolong survival without severe toxicity, highlighting the need for standardized Phase III trials to establish clinical guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Punjab Medical College, Punjab, Pakistan.
- Shalamar Medical and Dental College: Shalamar Medical and Dental College, Lahore, Pakistan.
- King Edward Medical College: King Edward Medical University, Lahore, Pakistan.
- Yale New Haven Hospital, New Haven, 06510, USA.
- Nishtar Medical University, Multan, Pakistan.
- University of Medical Sciences and Technology, Khartoum, Sudan.
Zitieren
APA
Firdous, J., Asif, A. E., Haris, H. M., Iqbal, U., Khalid, M., Zahid, H. F., Mubarika, M., Abufatima, I. O., Amin, M. H. J., Hafeez, S., Jabeen, F., Shahzaib, M., Fatima, N., Kumar, N., Sen, S., & Hassan, A. (2026). Efficacy and safety of ketogenic diet in glioblastoma: an updated systematic review and meta-analysis. Neurological Sciences, 47(5). https://doi.org/10.1007/s10072-026-09035-y
Vancouver
Firdous J, Asif AE, Haris HM, Iqbal U, Khalid M, Zahid HF, et al. Efficacy and safety of ketogenic diet in glioblastoma: an updated systematic review and meta-analysis. Neurological Sciences. 2026;47(5). doi:10.1007/s10072-026-09035-y
BibTeX
@article{Firdous2026,
author = {Firdous, Jawaria and Asif, Abdul Eizad and Haris, Hafiz Muhammad and Iqbal, Uzair and Khalid, Muddassir and Zahid, Hafiza Fatima and Mubarika, Moosa and Abufatima, Iman Osman and Amin, Mohammed Hammad Jaber and Hafeez, Sadia and Jabeen, Farha and Shahzaib, Muhammad and Fatima, Noor and Kumar, Nikil and Sen, Shuvendu and Hassan, Anid},
title = {Efficacy and safety of ketogenic diet in glioblastoma: an updated systematic review and meta-analysis},
journal = {Neurological Sciences},
year = {2026},
volume = {47},
number = {5},
doi = {10.1007/s10072-026-09035-y}
}
EUVIMED